Citigroup Forecasts Strong Price Appreciation for Albemarle (NYSE:ALB) Stock

Key Points

• Citigroup raised its price target on Albemarle from $210 to $225 and kept a neutral rating, implying about 10.45% upside from the prior close.
• Other analysts have also turned more constructive, with firms like Robert W. Baird, Bank of America, and Mizuho lifting targets after Albemarle’s recent results. The stock now has a consensus rating of Hold with an average target price of $189.04.
• Albemarle’s latest earnings beat expectations sharply, posting $2.95 EPS versus $1.24 expected and revenue of $1.43 billion, up 32.7% year over year. The strong quarter helped push the stock higher in trading.

Albemarle (NYSE:ALB - Get Free Report) had its target price upped by equities researchers at Citigroup from $210.00 to $225.00 in a research note issued on Friday,Benzinga reports. The firm currently has a "neutral" rating on the specialty chemicals company's stock. Citigroup's price objective indicates a potential upside of 10.45% from the stock's previous close.

Several other analysts have also issued reports on the stock. Mizuho boosted their price target on shares of Albemarle from $185.00 to $205.00 and gave the stock a "neutral" rating in a research report on Thursday. Robert W. Baird lifted their target price on shares of Albemarle from $210.00 to $236.00 in a research note on Thursday. Oppenheimer lifted their target price on shares of Albemarle from $216.00 to $222.00 and gave the stock an "outperform" rating in a research note on Monday, April 13th. Bank of America lifted their target price on shares of Albemarle from $190.00 to $225.00 and gave the stock a "buy" rating in a research note on Tuesday, April 21st. Finally, BMO Capital Markets lifted their target price on shares of Albemarle from $145.00 to $210.00 and gave the stock an "outperform" rating in a research note on Tuesday, January 20th. Thirteen research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $189.04.

Albemarle Stock Performance

Shares of Albemarle stock traded up $5.37 during trading on Friday, hitting $203.72. 3,125,911 shares of the company's stock were exchanged, compared to its average volume of 2,600,313. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.57 and a current ratio of 2.23. The business has a 50-day simple moving average of $179.56 and a 200-day simple moving average of $154.41. Albemarle has a 52-week low of $53.70 and a 52-week high of $221.00. The stock has a market capitalization of $24.02 billion, a price-to-earnings ratio of -59.74, a PEG ratio of 1.38 and a beta of 1.36.

Albemarle (NYSE:ALB - Get Free Report) last issued its earnings results on Wednesday, May 6th. The specialty chemicals company reported $2.95 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.24 by $1.71. Albemarle had a negative net margin of 5.00% and a positive return on equity of 5.20%. The firm had revenue of $1.43 billion during the quarter, compared to analysts' expectations of $1.34 billion. During the same quarter last year, the company posted ($0.18) earnings per share. The firm's revenue was up 32.7% compared to the same quarter last year. On average, research analysts forecast that Albemarle will post 8.72 EPS for the current year.

Insider Buying and Selling at Albemarle

In related news, CEO J Kent Masters sold 11,783 shares of Albemarle stock in a transaction that occurred on Tuesday, March 10th. The shares were sold at an average price of $170.81, for a total value of $2,012,654.23. Following the completion of the transaction, the chief executive officer owned 134,628 shares in the company, valued at approximately $22,995,808.68. The trade was a 8.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.42% of the company's stock.

Institutional Trading of Albemarle

Several institutional investors and hedge funds have recently bought and sold shares of ALB. Strategic Advocates LLC purchased a new stake in Albemarle in the 3rd quarter valued at $25,000. MH & Associates Securities Management Corp ADV purchased a new position in Albemarle during the 4th quarter worth $26,000. BOKF NA raised its position in Albemarle by 5,771.4% during the 3rd quarter. BOKF NA now owns 411 shares of the specialty chemicals company's stock worth $33,000 after buying an additional 404 shares during the last quarter. Cromwell Holdings LLC raised its position in Albemarle by 36.8% during the 3rd quarter. Cromwell Holdings LLC now owns 413 shares of the specialty chemicals company's stock worth $34,000 after buying an additional 111 shares during the last quarter. Finally, Elyxium Wealth LLC purchased a new position in Albemarle during the 4th quarter worth $34,000. Hedge funds and other institutional investors own 92.87% of the company's stock.

Trending Headlines about Albemarle

Here are the key news stories impacting Albemarle this week:

• Positive Sentiment: Q1 results materially beat expectations — Albemarle reported $2.95 EPS vs. $1.24 consensus and revenue of $1.43B (up ~33% YoY), driven by higher lithium pricing and volumes and a ~70% lift in Energy Storage sales. This is the main driver behind the stock’s upward move. Albemarle Reports First Quarter 2026 Results
• Positive Sentiment: Earnings-call tone and outlook signaled strong momentum — management commentary and the call transcript emphasized improving lithium market dynamics and operational momentum, supporting higher earnings visibility. Earnings Call Transcript
• Positive Sentiment: Robert W. Baird raised its price target to $236 (material upside vs. recent levels), providing a bullish analyst endorsement that likely amplified buying. Baird Adjusts ALB Price Target
• Neutral Sentiment: Mizuho raised its target to $205 and kept a neutral rating — a modest upgrade that affirms the beat but implies limited near-term upside from that house. Mizuho Price Target
• Neutral Sentiment: Albemarle updated FY‑2026 revenue guidance to roughly $5.7–$6.0B (in line with consensus), which reduces uncertainty but wasn’t a clear upside surprise on its own. Q1 Presentation / Guidance
• Neutral Sentiment: Zacks and other outlets compared Albemarle vs. peers for value and highlighted the company’s improved operating metrics — useful for longer-term investors but less immediately market-moving than the beat and upgrades. LYB or ALB: Value Comparison
• Negative Sentiment: Wells Fargo raised its target to $200 but maintained an "equal weight" rating — their target implies limited upside/possible slight downside versus recent levels, a cautionary signal for some investors. Wells Fargo View

About Albemarle

Albemarle Corporation is a leading global specialty chemicals company primarily engaged in the production and distribution of lithium, bromine, and catalysts. Its lithium segment supplies key components used in rechargeable batteries for electric vehicles, portable electronics, and grid storage systems. The company's bromine specialty products serve a wide range of industries, including oil and gas drilling fluids, fire safety solutions, and water treatment. In its catalysts division, Albemarle provides products for petroleum refining, chemical processing and emissions control.

Founded in 1994 as a spin-off from Ethyl Corporation, Albemarle has grown through strategic acquisitions and capacity expansions to become one of the world's foremost chemical producers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.